Skip to content

Advertisement

  • Research
  • Open Access
  • Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Adverse effects in children exposed to maternal HIV and antiretroviral therapy during pregnancy in Brazil: a cohort study

  • Adriane M. Delicio1, 2, 3Email author,
  • Giuliane J. Lajos1,
  • Eliana Amaral1,
  • Fernanda Cavichiolli1,
  • Marina Polydoro1 and
  • Helaine Milanez1
Reproductive Health201815:76

https://doi.org/10.1186/s12978-018-0513-8

Received: 30 November 2017

Accepted: 20 April 2018

Published: 10 May 2018

Abstract

Background

Antiretroviral therapy (ART) in pregnancy was associated with a drastic reduction in HIV mother-to-child transmission (MTCT), although it was associated with neonatal adverse effects. The aim of this study was to evaluate the neonatal effects to maternal ART.

Methods

This study was a cohort of newborns from HIV pregnant women followed at the CAISM/UNICAMP Obstetric Clinic from 2000 to 2015. The following adverse effects were evaluated: anemia, thrombocytopenia, liver function tests abnormalities, preterm birth, low birth weight and congenital malformation. Data collected from patients’ files was added to a specific database. Descriptive analysis was shown in terms of absolute (n) and relative (%) frequencies and mean, median and standard deviation calculations. The association between variables was tested through Chi-square or Fisher exact test (n < 5) and relative risk (RR) with its respective p values for the categorical ones and t-Student (parametric data) or Mann-Whitney (non-parametric data) for the quantitative ones. The significant level used was 0.05. A multivariate Cox Logistic Regression was done. Statistical analysis was performed using SAS version 9.4.

Results

Data from 787 newborns was analyzed. MTCT rate was 2.3%, with 0.8% in the last 5 years. Observed neonatal adverse effects were: liver function tests abnormalities (36%), anemia (25.7%), low birth weight (22.5%), preterm birth (21.7%), children small for gestational age (SGA) (18%), birth defects (10%) and thrombocytopenia (3.6%). In the multivariate analysis, peripartum CD4 higher than 200 cells/mm3 was protective for low birth weight and preterm birth, and C-section was associated with low birth weight, but not with preterm birth. Neonatal anemia was associated with preterm birth and exposure to maternal AZT. Liver function tests abnormalities were associated with detectable peripartum maternal viral load and exposure to nevirapine. No association was found between different ART regimens or timing of exposure with preterm birth, low birth weight or congenital malformation.

Conclusion

Highly active antiretroviral treatment in pregnant women and viral load control were the main factors associated with MTCT reduction. Antiretroviral use is associated with a high frequency but mainly low severity adverse effects in newborns.

Keywords

HIVToxicityAdverse effectsAntiretroviral therapyPregnancyNewborn

RESUMO

Introdução

O uso da terapia antirretroviral (TARV) na gestação se associou a dramática redução da transmissão vertical (TV) do HIV, porém demonstrou poder estar relacionado a efeitos adversos neonatais. O objetivo deste estudo foi avaliar os efeitos neonatais decorrentes da exposição à TARV materna.

Métodos

estudo observacional analítico de uma coorte de recém-nascidos de gestantes infectadas pelo HIV atendidos no Serviço de Obstetrícia do CAISM/UNICAMP entre 2000 e 2015. Foram avaliados os seguintes efeitos adversos: anemia, plaquetopenia, alteração hepática, prematuridade, baixo peso e malformação congênita. Os dados foram coletados dos prontuários dos pacientes e inseridos em banco específico. A análise descritiva foi realizada por meio de frequências simples (n) e relativas (%) e cálculos de média, desvio-padrão e mediana. As associações entre variáveis foram testadas por meio do Qui-quadrado ou Exato de Fisher (n < 5) e Razão de Risco com respectivo valor de p para as categóricas e por meio do t Student (dados paramétricos) ou Mann-Whitney (não-paramétricos) para as quantitativas. O nível de significância foi de 0,05. A análise multivariada foi realizada através da Regressão Logística de COX. No processamento e análise dos dados, foi utilizado o programa SAS 9.4.

Resultados

foram analisados dados de 787 recém-nascidos. A taxa de TV do HIV foi de 2,3%, sendo 0,8% nos últimos 5 anos. Os efeitos adversos observados foram alteração hepática (36%), anemia (25,7%), baixo peso (22,5%), prematuridade (21,7%), crianças pequenas para idade gestacional (PIG) (18%), malformações congênitas (10%) e plaquetopenia (3,6%). Em análise multivariada, o CD4 periparto maior que 200 células/mm3 foi protetor para baixo peso e prematuridade, e a cesárea esteve associada ao baixo peso ao nascimento, mas não ao parto prematuro. A anemia esteve associada ao parto prematuro e à exposição a zidovudina materna. A alteração hepática esteve associada à carga viral materna periparto detectável e à exposição a nevirapina. Não houve associação entre diferentes esquemas de TARV e tempo de exposição às drogas maternas com prematuridade, baixo peso e malformação congênita.

Conclusão

a TARV potente materna com consequente controle da carga viral é o maior fator responsável pela redução da TV do HIV. Ela está associada a frequência elevada de efeitos adversos no recém-nascido, porém a maioria de menor gravidade.

Palavras-chave

HIVToxicidadeEfeitos adversosTerapia antirretroviralGestaçãoRecém-nascido

Plain English summary

HIV treatment during pregnancy controls maternal disease and reduces the risk of transmitting the virus to the baby. However, medication can cause some adverse effects in newborns such as anemia and liver changes, besides low birth weight or birth before the baby is completely mature. Our study was an investigation about the impact of the antiretroviral therapy over infants’ health. We studied information on 787 children born from HIV positive women between 2000 and 2015 at the Women’s Hospital at UNICAMP. After data analysis, we observed that the HIV transmission to the baby was low, especially in the last five years of the research. We also found a high occurrence of liver changes (36%), anemia (25.7%), low birth weight (22.5%), premature babies (21.7%) and birth defects (10%). Of these findings, prematurity, low birth weight or birth defects were not caused by the medication used during pregnancy. On the other hand, anemia and liver changes in the babies could have been caused by the mothers’ medication. From our study we concluded that, despite the high occurrence of side effects in the children born from mothers who tested positive for HIV, they are not severe, confirming the need for mother to take medication during pregnancy so the children can be born free from HIV.

Background

Around 36.7 million people are infected with human immunodeficiency virus (HIV) in the world. Of the 1.8 million new infections in 2016, almost half were women and 160,000 were children under 15 years who were infected through mother-to-child transmission (MTCT) [1].

MTCT can occur during pregnancy, delivery or breastfeeding. With no intervention MTCT risk was near 40% [2, 3]. Antiretroviral therapy (ART) for pregnant women is the best intervention to reduce the risk of infection to rates lower than 2%, increasing maternal and infant life expectancy [4, 5].

Through the years, the monotherapy with zidovudine recommended in the 1994 ACTG 076 protocol changed to a 3-drug antiretroviral therapy (ART). World Health Organization (WHO) treatment guidelines in 2013 recommended the universal use of ART in HIV infected pregnant women (B+ Option), independently of the CD4 count or the diseases status [6, 7]. ART should be maintained after birth to control maternal disease and to prevent MTCT and sexual HIV transmission (7). The treatment to HIV pregnant women follows the guidelines to ART in HIV infected adults [8].

The effects on the child and the ART safety use in the mother has been demonstrated through the years. Despite the unquestionable benefits of ART in reducing MTCT of HIV and the differences in the placental and pharmaco-kinetic transference of ART during pregnancy, every drug carries a potential risk for adverse effects [9]. The progressive presence of maternal antiretroviral in meconium with the increased gestational age demonstrates the fetal exposure to these drugs [10]. The adverse effects described in most of the studies are mainly hematological, hepatic and mitochondrial changes, preterm birth and low birth weight, neonatal mortality, fetal growth restriction, congenital malformation and viral resistance [1114].

The Women’s Hospital at University of Campinas School of Medical Sciences (CAISM/UNICAMP) has maintained a program for pregnant women infected with HIV since 1988, and has accumulated great experience in the use of ART. The aim of this study was to evaluate adverse hematologic and hepatic effects, preterm birth and low birth weight in a cohort of infants whose mothers had HIV infection and were followed at the Obstetrics Clinic in a public university hospital in Brazil.

Methods

Observational analytic study based on the evaluation of a historic cohort of pregnant women infected with HIV and their exposed newborns seen at the Obstetrics Clinic at the University of Campinas School of Medical Sciences (CAISM/UNICAMP) between 2000 and 2015. CAISM is the reference hospital for high risk pregnancy in Campinas, the second biggest city in the State of São Paulo with 1.2 inhabitants and an Human Development Index (HDI) of 0.8. Mostly, CAISM serves pregnant women without health insurance and from low socioeconomic status. Data about the women and their newborns was collected from the clinical files and from the epidemiologic Health Surveillance Agency. A specific form was developed to collect all the information.

The following variables were analyzed: pregnant women’s epidemiological and clinical characteristics, regimens of ART used, mode of delivery, MTCT of HIV, newborn characteristics (weight, height, age by Capurro, Apgar, birth defects, neonatal disease), use of post-natal prophylaxis and newborn’s laboratorial results (anemia, thrombocytopenia, liver function tests abnormalities). Neonatal death was defined as death of a live birth up to 28 days and fetal death as birth with no signs of life after the 20th week of gestational age. Time of ART introduction was described in gestational weeks; women in use of ART in the last menstrual period were considered in treatment at conception. The combination of antiretroviral drugs considered for the global analysis were: monotherapy with zidovudine (AZT); double therapy with nucleoside reverse transcriptase inhibitors (NRTI) and combined therapy (ART). Combined therapy was defined as a combination of at least three drugs with no less than one protease inhibitor (PI) or one non-nucleoside reverse transcriptase inhibitor (NNRTI). Women using the PI darunavir (DRV), lopinavir (LPV) and atazanavir (ATV) also received booster of ritonavir (R).

To evaluate the adverse effects of antiretroviral medication in the newborns the main outcomes were: preterm birth (defined as gestational age under 37 weeks or very preterm birth under 34 weeks), low birth weight (defined as birth weight less than 2500 g or very low birth weight under 1500 g), and children small for gestational age (SGA) [15]. Abnormal laboratory results included anemia (hemoglobin < 13,5 g/dl), thrombocytopenia (platelets < 150,000/ml), liver function tests abnormalities (at least one: alanine aminotransferase-ALT > 31 U/l, aspartate aminotransferase-AST > 122 U/l, alkaline phosphatase-ALCPH > 250 U/l, gamma-glutamyl transferase-GGT > 151 U/L, bilirubin > 1,0 mg/dl) [16].

All newborns exposed to HIV infection were followed at the Pediatric Immunodeficiency Service at the same University Hospital. The cases with no final HIV infection diagnosis due to loss of follow-up were contacted by phone. This study was approved by the Institution’s Ethics in Research Committee (protocol #351/2006).

Descriptive analysis was shown in terms of absolute (n) and relative (%) frequencies, mean, median and standard deviation. Chi-square or Fisher exact test (n < 5) was used to analyze the association between the categorical variables. For the continuous variables, the Student t-test (parametric data) or Mann-Whitney (non-parametric data) were used. The specific effects of the different antiretroviral regimens were analyzed using relative risk (RR) with its respective p values. A multivariate Cox Logistic Regression analysis was done. A 95% confidence interval (CI) and a significant level of 0.05 were used. Statistical analysis was performed using SAS version 9.4.

Results

Between 2000 and 2015, 47,841 births occurred at the site where this study took place. From these, 801 were pregnant women infected with HIV, with a 1.67% prevalence rate. Figure 1 shows all the eligible cases, dropped patients and final newborn numbers included in the analysis (n = 787). The MTCT rate was 2.3%. In the last 5 years, of the 350 infected pregnant women, there were only three cases of HIV transmission, all of them from women with low adherence to ART and substance abuse.
Figure 1
Fig. 1

Fluxogram of pregnant women infected with HIV and exposed children between 2000 and 2015. ART antiretrovitral therapy

Pregnant women, prenatal care and delivery characteristics

The mean age of the pregnant women was 28 years; 61.2% were white, 60.9% completed elementary school and the median parity was one child. Pregnancy was planned in 25.7% of the cases. Exposure to HIV was heterosexual in 93% of the women and 10 of them (2.5%) had acquired the infection through MTCT.

Sixty-two percent of the women knew about their HIV status before the pregnancy, 47% had taken some antiretroviral drug previously and 27% were using ART at conception. The most used combination was the two NRTI and one PI or one NNRTI, with 81 (10.2%) using Efavirenz (EFV) at conception. The median gestational week at the start of prenatal care was 17.1 weeks and the mean number of prenatal visits was 7.6.

A little more than half (52.7%) of the women presented at least one of the following gestational complications: substance abuse (crack) in 14.3%, smoking (14.3%), preterm labor (14.2%), hypertension (7.4%), alcoholism (5.8%), intrauterine grow restriction (4.4%) and psychiatric problems (2.9%), among others. At least 767 women (84.8%) presented at least one infection: urinary infection (34.9%), bacterial vaginosis (33.8%), Streptococcus B colonization (33.4%), intracervical papillomavirus/neoplasia (14.3%), hepatitis C (7.6%), latent tuberculosis (5,6%), syphilis (5.2%), genital herpes (2.2%), active tuberculosis (1.7%), and hepatitis B (0.4%). Only four patients presented multidrug resistance (3.3%).

Fifty-one percent of the pregnant women were classified into the CDC stage 2 and 18.5% were classified as having Acquired Immunodeficiency Syndrome (AIDS). Only 32 women (4.1%) presented opportunistic infections during pregnancy. Fifteen (1.9%) women did not use antiretroviral therapy while pregnant because the HIV diagnosis was done during labor. The 81 patients in use of efavirenz in the first trimester had the drug changed to PI during the prenatal care, except for one which maintained it throughout pregnancy. Only four pregnant women were using EFV towards the end of gestation, including three which started EFV in the second trimester. Twenty-three (2.9%) women used monotherapy with AZT and 11 (1.4%) used the double therapy (zidovudine e lamivudine). Most of the pregnant women used combined ART: 17% with two NRTI and nevirapine (NVP), 17% with two NRTI and nelfinavir (NFV), 54% with two NRTI and lopinavir/ritonavir (LPV/R), 5% with two NRTI and other PI (26 with ATV/R, 6 with indinavir, 3 with darunavir, 3 with saquinavir, and 2 with fosamprenavir). Five women used a combination of two NRTI with NVP and PI simultaneously (3 with LPV/R, 1 with ATV/R and 1 with NFV, included in their respective groups). The most used NRTI were zidovudine (AZT) and lamivudine (3TC). AZT was changed to tenofovir (TDF) in 41 cases, to stavudine in seven cases and to abacavir in one case. The AZT combination with TDF cases (17 patients) were excluded from the specific analysis. The integrase inhibitor raltegravir (RAL) was added to the ART regimen in seven cases (four cases included in the LPV/R group and three cases with DRV/R, included in the Regimens with other PI group), mostly in the late gestational weeks (Table 1).
Table 1

Characteristics of pregnant women infected with HIV at CAISM/UNICAMP from 2000 to 2015

Characteristics

n

Median (%)

Age (years)

793

28 (13–46)

Parity

793

1 (0–9)

Schooling years (n = 769)

  < 8

468

60.9

 8–11 yrs.

248

32.2

  > 12

39

5.1

 No schooling

14

1.8

Ethnicity: White

485

61.2

HIV diagnosis (n = 789)

 Prior to pregnancy

489

62.5

 During pregnancy

294

37.5

In use of ART at conception (n = 787)

217

27.6

In use of Efavirenz at conception (n = 793)

81

10.2

Planned pregnancy (n = 382)

98

25.7

Heterosexual transmission (n = 408)

380

93.1

Opportunistic disease during pregnancy (n = 785)

32

4.1

First CD4 median (cel/ml)

734

444 (3–1915)

Peripartum CD4 median (cel/ml)

175

552 (5–2164)

Median time of ART use (days)

410

152.5 (4–292)

Peripartum Viral Load < 50 (copies/ml) (n = 732)

432

58.9

CDC classification (n = 758)

 1

227

29.9

 2

391

51.6

 3

140

18.5

Coinfections during pregnancy (n = 787)

667

84.8

Obstetrics complications (n = 792)

417

52.7

ART adherence during prenatal care

649

84.3

Changed ART (n = 776)

149

19.2

Premature rupture of membranes (n = 773)

121

15.7

Labor (n = 447)

188

42.1

Intravenous AZT (n = 775)

735

94.8

Antiretroviral regimens during pregnancy (n = 793)

 None

15

1.9

 Monotherapy with AZT

23

2.9

 NRTI + NRTI

11

1.4

 NRTI + NRTI + NVP

138

17

 NRTI + NRTI + NFV

135

17

 NRTI + NRTI + LPV/R

428

54

 Regimens with other PI

40

5

 NRTI + NRTI + EFV

3

0.4

TOTAL

793

100

ART antiretroviral therapy, AZT zidovudine, NRTI nucleos(t)ide reverse transcriptase inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitor, NVP nevirapine, EFV efavirenz, PI protease inhibitor, NFV nelfinavir, LPV lopinavir, R ritonavir, CDC Centers for Disease Control and Prevention

The median time of antiretroviral therapy during pregnancy was 152.5 days. The median initial CD4 was 444 cells/ml (varying from 3 to 1915) and the median perinatal count was 552 cells/ml. The median viral load in the first count was 1371 copies/ml, with 432 (58.9%) women with undetectable viral load in the end of the pregnancy.

Intravenous AZT was used in 94.8% of the cases. Cesarean section was done in 92.8% of cases, mostly due to the HIV infection, according to the hospital guidelines between 2005 to 2015. There were only four episiotomies in the vaginal births and 42.1% of women went into labor, with 15.7% having premature rupture of the membrane.

Newborn characteristics

Of the 787 newborns, 384 (50.7%) were females. The birth weight and the mean length were 2850 g and 47 cm respectively. The median age at birth by the Capurro method was 38 weeks. One hundred and sixty-seven (21.7%) were preterm and 2.9% were very preterm birth. There were 22.5% low birth weight newborns, 3.6% with very low birth weight and 18% small for gestational age (SGA). Ninety-nine percent received an Apgar higher than 7 in the 5th minute.

All newborns received neonatal AZT oral prophylaxis. During follow-up, 81.3% received AZT for six weeks and 17.1% for four weeks. Only one newborn did not use prophylactic medication after hospital discharge. Twenty-four newborns (3.1%) received nevirapine associated with AZT in the first week of life to maximize the neonatal prophylaxis. Despite dispensation of cabergoline immediately after birth to every new mother and the recommendation to suspend breastfeeding, two newborns (0.3%) were breastfed.

Two hundred and nine (27.2%) newborns presented at least one disease in the neonatal period. The most common neonatal complications were: respiratory distress (15), neurologic disorders (14), newborn transitory tachypnea (11), hyaline membrane disease (5), neutropenia (5), hypoglycemia (5), withdrawal syndrome from maternal substance abuse (3), hypothyroidism (3) and myocarditis associated to ART (1). The most frequent infectious diseases were: syphilis (13), pneumonia (6), sepsis (5), cytomegalovirus (4), toxoplasmosis (3), meningitis (3), hepatitis C (2), varicella (1) and urinary tract infection (1).

Seventy-nine (10%) children presented congenital malformations: 23 in the nervous system, 21 had cardiopathy, 20 had hemangiomas and other skin problems, 12 in the urinary tract, 11 had muscle and skeletal anomalies, 3 had genital malformations, 3 with genetic anomalies and 2 had gastrointestinal congenital problems.

As for adverse effects, 36% of the children presented liver function tests abnormalities, 25.7% had anemia and 3.6% had thrombocytopenia at birth.

Association between prenatal characteristics and neonatal adverse effects

Low birth weight was associated with hypertension (RR 2.01 CI 1.26–3.2), smoking (RR 1.73 CI 1.12–2.67), substance abuse (RR 1.61 CI 1.04–2.48) and C-section in multivariate analysis (RR 1.96 CI 1.09–3.52). CD4 higher than 200 cells/mm3 was protective for low birth weight (RR 0.47 CI 0.29–0.77) (Table 2).

Preterm birth was associated with maternal AIDS (RR 1.80. CI 1.20–2.7), but not associated with cesarean (RR 1.43 CI 0.85–2.39). CD4 higher than 200 cells/mm3 was protective for preterm birth (RR 0.54 CI 0.37–0.79) (Table 2).

In the multivariate analysis, neonatal anemia was associated with preterm birth (RR 1.44 CI 1.04–1.99). The occurrence of liver function tests abnormalities was associated with perinatal maternal detectable viral load (RR 2.37 CI 1.52–3.68) (Table 2).
Table 2

Comparative analysis between children exposed to NNRTI and PI at CAISM/UNICAMP from 2000 to 2015

Variables

NNRTI

PI

p*

RR

CI 95%

n

%

n

%

Gestational age (Capurro)

    

0.2212

  

 <37 weeks

25

17.7

130

22.5

 

0.79

0.53–1.16

 >=37 weeks

116

82.3

449

77.5

 

1

 

Birth weight

    

0.4214

  

 <2500 g

28

19.7

135

22.8

 

0.86

0.59–1.25

 >=2500 g

114

80.3

456

77.2

 

1

 

Weight adequacy for GA

    

0.0051

  

 Adequate for GA

126

89.4

449

77.1

 

1

 

 Small for GA

14

9.9

118

20.3

 

0.48

0.29–0.81

 Large for GA

1

0.7

15

2.6

  

0.04–1.91

5th minute Apgar

    

0.9752

  

 <7

1

0.7

4

0.7

 

1.03

0.18–5.97

 >=7

141

99.3

584

99.3

 

1

 

Neonatal disease

    

0.4002

  

 Yes

33

24.1

160

27.6

 

0.86

0.60–1.23

 No

104

75.9

419

72.4

 

1

 

Birth defect

    

0.5148

  

 Yes

12

8.5

61

10.3

 

0.84

0.49–1.44

 No

130

91.5

533

89.7

 

1

 

Anemia

    

0.0403

  

 Yes

39

32.2

129

23.3

 

1.43

1.02–2.01

 No

82

67.8

424

76.7

 

1

 

Thrombocytopenia

    

0.2841

  

 Yes

2

1.7

22

4

 

0.46

0.12–1.74

 No

119

98.3

532

96

 

1

 

Hepatic changes

    

< 0.0001

  

 Yes

21

80.8

100

31.4

 

7.74

2.99–20.01

 No

5

19.2

218

68.6

 

1

 

TOTAL

142

100

594

100

   

GA gestational age, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor

(#) Numbers are different due to the lack of information on some patients

*Chi-square

Association between maternal ART exposure and neonatal adverse effects

Use of NVP showed a higher occurrence of anemia (p = 0.0403, RR 1.43 CI 1.02–2.01) and liver function tests abnormalities (p < 0.0001, RR 7.74 CI 2.99–20.01) at birth when compared to the PI use (Table 3).
Table 3

Comparative analysis between children exposed to different protease inhibitors at CAISM/UNICAMP from 2000 to 2015

Variables

ATV

NFV

LPV/R

p*

ATV x LPV/R

NFV x LPV/R

ATV x NFV

n

%

n

%

n

%

RR

CI 95%

RR

CI 95%

RR

CI 95%

Gestational age (weeks)

 <34 weeks

0

0

4

3.1

11

2.7

0.0922

NC

 

0.71

0.47–1.07

NC

 

 >=34 weeks

25

100

126

96.9

402

97.3

  

1.00

   

Gestational age (Capurro)

 <37 weeks

6

24

22

16.9

99

24

0.0922

1.00

0.41–2.44

0.71

0.47–1.07

1.43

0.63–3.26

 >=37 weeks

19

76

108

83.1

314

76

1.00

 

1.00

 

1.00

 

Birth weight

 <2500 g

5

19.2

24

18.2

104

24.6

0.1242

0.74

0.29–1.92

0.74

0.50–1.10

1.06

0.44–2.57

 >=2500 g

21

80.8

108

81.8

318

75.4

1.00

 

1.00

 

1.00

 

Birth weight

 <1500 g

0

0

8

6.1

13

3.1

0.023

NC

 

1.5

0.85–2.65

NC

 

 1500 g - 2499 g

5

19.2

16

12.1

91

21.6

  

0.59

0.36–0.95

1.46

0.62–3.45

 >=2500 g

21

80.8

108

81.8

318

75.4

  

1.5

 

1.00

 

Weight adequacy for GA

 Adequate for GA

19

76

110

83.3

312

75.4

0.0004

1.00

 

1.00

 

1.00

 

 Small for GA

5

20

15

11.4

97

23.4

0.85

0.33–2.23

0.51

0.31–0.85

1.7

0.71–4.03

 Large for GA

1

4

7

5.3

5

1.2

2.90

0.46–18.31

2.24

1.34–3.71

0.85

0.13–5.56

5th minute Apgar

 <7

0

0

1

0.8

2

0.5

0.5603**

  

1.4

0.28–6.97

  

 >=7

25

100

131

99.2

418

99.5

  

1.00

   

Neonatal disease

 Yes

8

30.8

27

21.3

122

29.4

0.0723

1.06

0.47–2.38

0.71

0.49–1.04

1.5

0.71–3.15

 No

18

69.2

100

78.7

293

70.6

1.00

 

1.00

 

1.00

 

Birth defect

 Yes

1

3.8

16

12.1

43

10.1

0.5135

0.37

0.05–2.67

1.16

0.74–1.82

0.33

0.05–2.30

 No

25

96.2

116

87.9

382

89.9

1.00

 

1.00

 

1.00

 

Anemia

 Yes

2

8.3

33

27.5

92

23.1

0.3183

0.32

0.08–1.33

1.2

0.85–1.69

0.28

0.07–1.14

 No

22

91.7

87

72.5

307

76.9

1.00

 

1.00

 

1.00

 

Thrombocytopenia

 Yes

3

12.0

6

5.0

13

3.3

0.0755

3.49

1.16–10.45

1.4

0.71–2.76

2.05

0.75–5.56

 No

22

88.0

113

95.0

387

96.8

1.00

 

1.00

 

1.00

 

Hepatic changes

 Yes

5

25.0

28

90.3

63

24.1

<  0.0001

1.04

0.39–2.77

20.62

6.43–66.07

0.18

0.08–0.42

 No

15

75.0

3

9.7

198

75.9

1.00

 

1.00

 

1.00

 

TOTAL

26

 

132

 

425

        

GA gestacional age, ATV atazanavir, NFV nelfinavir, LPV lopinavir, R ritonavir

(#) Numbers are different due to the lack of information on some patients

(# #) Not calculated

*Chi-square, **Fisher Exact

Looking at the different protease inhibitors, the use of LPV increased the risk for low birth weight, specially between 1500 and 2499 g (p = 0.0230, RR 0.59 CI 0.36–0.95) and being small for the gestational age (SGA) (p = 0.0004, RR 0.51 CI 0.31–0.85) when compared to NFV use. NFV was associated with higher risk for liver function tests abnormalities (p < 0.0001, RR 20.62 CI 6.43–66.07) (Table 4).
Table 4

Comparative analysis of children exposed to tenofovir and zidovudine at CAISM/UNICAMP from 2000 to 2015

Variables

TDF

AZT

p*

RR

CI 95%

n

%

n

%

Gestational age (Capurro)

    

0.8962

  

 <37 weeks

8

21.1

153

22

 

0.95

0.44–2.03

 >=37 weeks

30

78.9

544

78

 

1

 

Birth weight

    

0.5221

  

 <2500 g

7

17.9

158

22.3

 

0.77

0.35–1.72

 >=2500 g

32

82.1

550

77.7

 

1

 

Weight adequacy for GA

    

0.3722

1

 

 Adequate for GA

28

73.7

563

80.3

 

1.29

0.60–2.76

 Small for GA

8

21.1

123

17.5

 

2.48

0.64–9.59

 Large for GA

2

5.3

15

2.1

   

5th minute Apgar

    

1.000**

  

 <7

0

0

5

0.7

   

 >=7

38

100

701

99.3

   

Neonatal disease

    

0.0056

  

 Yes

18

46.2

179

25.9

 

2.32

1.26–4.26

 No

21

53.8

512

74.1

 

1

 

Birth defect

    

0.0547**

  

 Yes

8

20

69

9.7

 

2.19

1.04–4.57

 No

32

80

641

90.3

 

1

 

Anemia

    

0.0030

  

 Yes

2

5.3

174

26.9

 

0.16

0.04–0.66

 No

36

94.7

473

73.1

 

1

 

Thrombocytopenia

    

0.6474**

  

 Yes

2

5.1

23

3.5

 

1.43

0.36–5.60

 No

37

94.9

624

96.5

 

1

 

Hepatic changes

    

0.0411

  

 Yes

19

51.4

101

34.2

 

1.86

1.02–3.41

 No

18

48.6

194

65.8

 

1

 

TOTAL

40

 

710

    

GA gestational age, TDF tenofovir, AZT zidovudine

(#) The numbers are different due to lack of information about some patients

(##) Not calculated

*Chi-square, **Fisher Exact

Comparing TDF and AZT, the exposure to TDF was associated with higher occurrence of neonatal diseases (p = 0.0056, RR 2.32 CI 1.26–4.26) and increased liver function tests abnormalities (p = 0.0411, RR 1.86 CI 1.02–3.41), besides lower risk of anemia at birth (p = 0.0030, RR 0.16 CI 0.04–0.66) (Table 5).
Table 5

Multivariate analysis of risk factors associated with neonatal adverse effects

Risk Factors

Birth weight

Relative Risk

Logistic Regression

Gestational age at birth

Relative Risk

Logistic Regression

Anemia

Relative Risk

Logistic Regression

Hepatic alterations

Relative Risk

Logistic Regression

<2500 g

>=2500 g

  

<37 weeks

>=37 weeks

Yes

No

Yes

No

n

%

n

%

RR CI 95%

RR CI 95%

n

%

n

%

RR CI 95%

RR CI 95%

n

%

n

%

RR CI 95%

RR CI 95%

n

%

n

%

RR CI 95%

RR CI 95%

Maternal age

 <=28 yrs

84

47.2

332

54.1

1

 

102

54.0

312

52.2

1

 

104

56.2

270

50.2

1

 

63

49.2

104

46.2

1

 

 >28 yrs

94

52.8

282

45.9

1.24 (0.92–1.66)

 

87

46.0

286

47.8

0.95 (0.71–1.26)

 

81

43.8

268

49.8

0.84 (0.62–1.12)

 

65

50.8

121

53.8

0.93 (0.66–1.31)

 

Hypertension

 No

157

88.7

583

95.6

1

 

175

93.1

562

94.6

1

 

181

97.8

499

93.4

1

 

120

94.5

212

94.6

1

 

 Yes

20

11.3

27

4.4

2.01 (1.26–3.20)

 

13

6.9

32

5.4

1.22 (0.69–2.14)

 

4

2.2

35

6.6

0.39 (0.14–1.04)

 

7

5.5

12

5.4

1.02 (0.48–2.18)

 

 No information

1

 

4

   

1

 

4

     

4

   

1

 

1

   

Diabetes during pregnancy

 No

160

94.7

523

93.4

1

 

168

96.0

511

93.1

1

 

160

94.7

469

93.2

1

 

106

93.8

212

95.1

1

 

 Yes

9

5.3

37

6.6

0.84 (0.43–1.64)

 

7

4.0

38

6.9

0.63 (0.30–1.34)

 

9

5.3

34

6.8

0.82 (0.42–1.61)

 

7

6.2

11

4.9

1.17 (0.54–2.51)

 

 No information

9

 

54

   

14

 

49

   

16

 

35

   

15

 

2

   

Coinfection during pregnancy

 No

19

10.7

96

15.8

1

 

24

12.8

91

15.3

1

 

26

14.1

79

14.8

1

 

22

17.3

31

13.9

1

 

 Yes

158

89.3

513

84.2

1.42 (0.89–2.29)

 

163

87.2

503

84.7

1.17 (0.76–1.80)

 

159

85.9

454

85.2

1.05 (0.69–1.59)

 

105

82.7

192

86.1

0.86 (0.54–1.35)

 

 No information

1

 

5

   

2

 

4

   

0

 

5

   

1

 

2

   

Smoking

 No

88

77.2

362

87.7

1

 

104

85.2

341

85.3

1

 

115

90.6

288

83.2

1

 

70

83.3

61

69.3

1

 

 Yes

26

22.8

51

12.3

1.73 (1.12–2.67)

 

18

14.8

59

14.8

1 (0.57–1.65)

 

12

9.4

58

16.8

0.6 (0.33–1.09)

 

14

16.7

27

30.7

0.64 (0.36–1.13)

 

 No information

64

 

201

   

67

 

198

   

58

 

192

   

44

 

137

   

Substance abuse

 No

95

78.5

381

87.4

1

 

111

86.0

360

85.1

1

 

121

90.3

304

82.8

1

 

75

80.6

66

61.7

1

1

 Yes

26

21.5

55

12.6

1.61 (1.04–2.48)

 

18

14.0

63

14.9

0.94 (0.57–1.55)

 

13

9.7

63

17.2

0.6 (0.34–1.07)

 

18

19.4

41

38.3

0.5 (0.34–0.96)

0.47 (0.27–0.83)

 No information

57

 

178

   

60

 

175

   

51

 

171

   

35

 

118

   

Alcoholism

 No

98

92.5

388

94.9

1

 

113

95.8

368

93.9

1

 

123

96.9

312

92.9

1

 

79

95.2

69

81.2

1

 

 Yes

8

7.5

21

5.1

1.37 (0.67–2.81)

 

5

4.2

24

6.1

0.73 (0.30–1.80)

 

4

3.1

24

7.1

0.51 (0.19–1.37)

 

4

4.8

16

18.8

0.38 (0.14–1.02)

 

 No information

72

 

205

   

71

 

206

   

58

 

202

   

45

 

140

   

First CD4 (cells/mm3)

 <200

31

18.0

59

10.5

1

 

34

19.2

55

9.9

1

 

24

13.8

59

11.7

1

 

20

17.1

21

9.6

1

 

 >=200

141

82.0

505

89.5

0.64 (0.43–0.94)

 

143

80.8

499

90.1

0.58 (0.40–0.85)

 

150

86.2

444

88.3

0.87 (0.57–1.34)

 

97

82.9

198

90.4

0.67 (0.42–1.09)

 

 No information

6

 

50

   

12

 

44

   

11

 

35

   

11

 

6

   

Peripartum CD4 (cells/mm3)

 <200

30

17.5

47

8.36

1

1

32

18.2

44

8.0

1

1

21

12.1

50

9.9

1

 

18

15.5

18

8.2

1

 

 >=200

141

82.5

515

91.6

0.55 (0.37–0.82)

0.47 (0.29–0.77)

144

81.8

508

92.0

0.53 (0.36–0.77)

0.54 (0.37–0.79)

152

87.9

453

90.1

0.85 (0.54–1.34)

 

98

84.5

201

91.8

0.6 (0.40–1.08)

 

 No information

7

 

52

   

13

 

46

   

12

 

35

   

12

 

6

   

Peripartum viral load

 Undetectable (<50 copies/ml)

92

54.8

343

60.4

1

 

99

56.3

336

60.5

1

 

106

60.9

302

59.7

1

 

58

49.2

168

76.0

1

1

 Detectable (>=50 copies/ml)

76

45.2

225

39.6

1.19 (0.88–1.62)

 

77

43.8

219

39.5

1.14 (0.85–1.54)

 

68

39.1

204

40.3

0.96 (0.71–1.31)

 

60

50.8

53

24.0

2.61 (1.44–2.97)

2.37 (1.52–3.68)

 No information

10

 

46

   

13

 

43

   

11

 

32

   

10

 

4

   

CDC classification

 1

47

26.9

177

30.4

1

 

44

24.2

180

31.5

1

 

49

27.4

158

30.4

1

 

40

32.8

63

28.1

1

 

 2

84

48.0

304

52.1

1.03 (0.72–1.48)

 

87

47.8

298

52.2

1.15 (0.80–1.65)

 

91

50.8

266

51.3

1.08 (0.76–1.52)

 

54

44.3

114

50.9

0.83 (0.55–1.25)

 

 3

44

25.1

102

17.5

1.44 (0.95–2.17)

 

51

28.0

93

16.3

1.8 (1.20–2.70)

 

39

21.8

95

18.3

1.23 (0.81–1.87)

 

28

23.0

47

21.0

0.96 (0.59–1.56)

 

 No information

3

 

31

   

7

 

27

   

6

 

19

   

6

 

1

   

Start of ART use

 Before pregnancy

41

23.6

102

17.1

1

 

42

22.7

101

17.4

1

 

32

17.6

101

19.2

1

 

23

18.7

76

34.1

1

1

 During pregnancy

133

76.4

495

82.9

0.74 (0.52–1.05)

 

143

77.3

480

82.6

0.78 (0.55–1.10)

 

150

82.4

424

80.8

1.09 (0.74–1.59)

 

100

81.3

147

65.9

1.74 (1.11–2.74)

1.5 (0.71–3.18)

 No information

4

 

17

   

4

 

17

   

3

 

13

   

5

 

2

   

Time of ART use during pregnancy

 <=15 days

1

1.0

7

2.2

1

 

2

1.9

6

1.9

1

 

1

1.2

7

2.3

1

 

1

1.5

4

1.9

1

 

 >15 days

97

99.0

307

97.8

1.92 (0.27–13.77)

 

102

98.1

302

98.1

1.01 (0.25–4.09)

 

84

98.8

295

97.7

1.77 (0.25–12.73)

 

67

98.5

206

98.1

1.23 (0.17–8.84)

 

 No information

80

 

300

   

85

 

290

   

100

 

236

   

60

 

15

   

NRTI

 AZT

158

303.8

550

252.3

1

 

171

275.8

533

260.0

1

 

174

98.9

473

92.9

1

1

101

84.2

194

91.5

1

 

 TDF

7

13.5

32

14.7

0.8 (0.41–1.60)

 

6

9.7

32

15.6

0.65 (0.29–1.47)

 

2

1.1

36

7.1

0.2 (0.05–0.79)

0.21 (0.05–0.83)

19

15.8

18

8.5

1.5 (0.92–2.45)

 

 No information

13

 

32

   

12

 

33

   

9

 

29

   

8

 

13

   

ART during pregnancy

 NRTI+ NRTI + NVP

28

17.4

110

19.7

1

 

34

20.0

103

18.9

1

 

38

4.1

79

2.9

1

 

20

2.6

3

0.2

1

1

 NRTI+ NRTI + NFV

24

14.9

108

19.4

0.9 (0.52–1.55)

 

28

16.5

102

18.8

0.87 (0.53–1.43)

 

33

3.6

87

3.2

0.85 (0.53–1.35)

 

28

3.6

3

0.2

1.04 (0.59–1.84)

0.95 (0.5–1.81)

 NRTI+ NRTI + LPV/R

104

64.6

318

57.1

1.22 (0.80–1.84)

 

103

60.6

319

58.6

0.98 (0.67–1.45)

 

92

9.9

307

11.4

0.71 (0.49–1.04)

 

63

8.2

198

14.7

0.28 (0.17–0.46)

0.39 (0.19–0.79)

 NRTI+ NRTI + ATV/R

5

3.1

21

3.8

0.95 (0.37–2.46)

 

5

2.9

20

3.7

0.81 (0.32–2.06)

 

2

0.2

22

0.8

0.26 (0.06–1.06)

 

5

0.7

15

1.1

0.29 (0.11–0.77)

0.48 (0.14–1.62)

 No information

17

 

57

   

19

 

54

   

20

 

43

   

12

 

6

   

Birht weight

 >=2500 g

            

139

75.5

427

79.4

1

 

99

78.0

177

78.7

1

 

 <2500 g

            

45

24.5

111

20.6

1.18 (0.84–1.64)

 

28

22.0

48

21.3

1.03 (0.68–1.56)

 

 No information

            

1

 

0

   

1

 

0

   

Gestational age at birth

 >=37 weeks

            

126

68.5

428

80.0

1

1

104

81.9

171

76.3

1

 

 <37 weeks

            

58

31.5

107

20.0

1.55 (1.13–2.11)

1.44 (1.04–1.99)

23

18.1

53

23.7

0.8 (0.51–1.26)

 

 No information

            

1

 

3

   

1

 

1

   

Mode of delivery

 Vaginal

21

11.8

32

5.2

1.87 (1.18–2.94)

1.96 (1.09–3.52)

22

11.6

29

4.8

1.90 (1.22–2.97)

1.43 (0.85–2.39)

10

5.4

36

6.7

0.84 (0.45–1.59)

 

12

9.4

9

4

1.64 (0.90–2.96)

 

 Cesarean

157

88.2

582

94.8

1

1

167

88.4

569

95.2

1

1

175

94.6

502

93.3

1

 

116

90.6

216

96

  

Preterm labor

 No

134

75.7

541

88.7

1

1

123

65.4

551

92.8

1

1

151

81.6

466

87.3

1

 

115

90.6

187

83.5

1

 

 Yes

43

24.3

69

11.3

1.93 (1.37–2.73)

2.08 (1.34–3.24)

65

34.6

43

7.2

3.30 (2.44–4.45)

3.33 (2.43–4.54)

34

18.4

68

12.7

1.36 (0.94–1.98)

 

12

9.4

37

16.5

0.64 (0.36–1.17)

 

 No information

1

 

4

   

1

 

4

   

0

 

4

   

1

 

1

   

ART antiretroviral therapy, NRTI nucleos(t)ide reverse transcriptase inhibitors, AZT zidovudine, TDF tenofovir, NVP nevirapine, NFV nelfinavir, LPV lopinavir, ATV atazanavir, R ritonavir, CDC Centers for Disease Control and Prevention

*Cox Logistic Regression

SGA children did not present higher occurrences of neonatal diseases (p = 0.1038), congenital malformation (p = 0.1902), anemia (p = 0.6578), liver function tests abnormalities (p = 0.9225) at birth or MTCT (p = 0.1759) when compared to children with adequate birth weight for gestational age (data not shown).

ART introduced prior to pregnancy was associated with higher preterm birth (p = 0.008) and with neonatal diseases (p < 0.0001). On the other hand, initiating ART during pregnancy was associated with higher instances of liver function tests abnormalities (p = 0.0024). There was no difference in the occurrence of congenital malformations regarding time of ART exposure during pregnancy (data not shown).

In multivariate analysis, there was no association between antiretroviral treatment regimen or time of ART exposure and preterm birth, low birth weight or birth defects. Compared to maternal AZT exposure, TDF use was less frequently associated with neonatal anemia (RR 0.21 CI 0.05–0.83). NVP use was associated with higher occurrence of neonatal liver function tests abnormalities (RR 0.39 CI 0.19–0.79), compared to maternal LPV/R exposure (Table 2).

Discussion

This study analyzed 793 pregnancies of HIV infected women and 787 exposed newborns and showed high rates of neonatal adverse effects. Low birth weight occurred in 22.5%, preterm birth in 22%, SGA children in 18% and very low birth weight in 4% of all cases. Similar results were found in another Brazilian study with 74 children exposed to maternal ART between 2001 and 2012, where 34.8% were exposed since conception, with preterm birth rates of 17.5% and low birth weight of 20.2%, proportionally higher in women with AIDS [17].

In our cohort, preterm birth rates were much higher than another more recent multicentric study comprised of 20 reference hospitals in Brazil which showed a preterm birth rate of 12.3% for a general population of pregnant women, including women infected with HIV [18].

Contrary to our data, another study evaluating 214 HIV infected pregnant women in Rio de Janeiro between 2005 and 2006 showed low occurrence of preterm birth, low birth weight, malformations or obstetric complications [19].

Studies on preterm birth and low birth weight in children exposed to maternal HIV sometimes showed conflicting results, considering many factors (socioeconomic, maternal age, body mass index, ethnicity, smoking, substance abuse, multiple gestation, previous preterm birth, uterine infection and bacterial vaginosis) besides maternal diseases, genital and plasmatic viral load or ART exposure can increase the risk of preterm birth and low birth weight [2022]. Most of the studies show high rates of preterm birth and low birth weight in children with maternal ART exposure, in line with our data.

In our study hypertension, smoking and substance abuse were associated with low birth weight while maternal AIDS were associated with preterm birth. On the other hand, in the multivariate analysis, only peripartum CD4 count lower than 200 cells/mm3 came up as a risk factor for preterm birth and low birth weight, and C-section as a risk factor for low birth weight but not for preterm birth. The association between severe immunosuppression and higher risk for preterm birth and low birth weight appears in most of the literature’s results [17].

C-section was associated with a higher occurrence of low birth weight since in situations of fetal grow restrictions there is a higher need for cesarean due to chronic fetal distress and low fetal reserves. The occurrence of C-sections was not associated with preterm birth since the institution’s protocol at that time included the recommendation for an elective C-section around 39 weeks of gestational age for patients infected with HIV to avoid iatrogenic prematurity. Nowadays, the institution guidelines recommend C-section only if the viral load is detectable after 35 weeks or for obstetrics’ reasons [23].

In our study, contrary to other published research, time of maternal ART exposure was not a risk factor for neonatal outcomes such as preterm birth and low birth weight. The increased risk for these two outcomes in children exposed to ART since conception was observed in a Latin America and Caribbean study of 1512 pregnant women and 1483 live births. It showed 19.8% preterm birth rates, 14.2% low birth weight, 12.6% SGA and 0.4% of neonatal deaths were associated with ART initiated prior to the pregnancy, smoking, low maternal body mass index, hospitalization and gestational hypertension [24]. A more recent cohort study from Tanzania which evaluated 3314 pregnant women infected with HIV also showed high rates of preterm birth (26%) associated with longer exposure to maternal drugs during pregnancy. The general rates for SGA was 21%, similarly to our study’s rate of 18%. Among the pregnant women which used PI regimens the preterm birth rate was 25% and the SGA was 13% [25] as in our study.

Data from a cohort of 9504 infected women in Botswana demonstrated that the HIV infection was associated with higher occurrence of stillbirth, preterm birth, SGA and perinatal death. Women in use of ART prior to pregnancy presented an even higher risk [26].

A study from Rio de Janeiro with 588 children exposed to maternal HIV between 1996 and 2010 showed an association between the use of ART in the first trimester and a higher occurrence of SGA, contrary to our findings [27].

Consistent with our data, a meta-analysis from 2007 showed no difference in instances of preterm birth among the various ART regimens. However, regimens with PI and ART use either before conception or early in pregnancy elevated the risk of preterm birth [28].

In our cohort, the different regimens of maternal ART evaluation demonstrated no association between AZT and TDF use with preterm birth or low birth weight. Nevertheless, a clinical trial (PROMISE trial) from six countries in sub-Saharan Africa and India showed an association between TDF exposure and higher rates of preterm birth and early neonatal death when compared to AZT exposure. Low birth weight and preterm birth were more frequent in the combined ART group compared to AZT monotherapy [29]. Data from the American Antiretroviral Pregnancy Registry from 1989 to 2013 also found an increased risk for low birth weight among patients utilizing AZT regimens [30].

In multivariate analysis of types of ART regimens, we found no association between a specific treatment regimen and higher occurrence of preterm birth and low birth weight, similarly to other studies [31]. We found no association of PI exposure and higher risk of low birth weight. It is currently considered that the maternal progesterone level reduction due to lower trophoblastic production in pregnant women using PI could be directly related to fetal weight and could explain preterm birth and low birth weight outcomes [32].

Various other studies also found no association between specific antiretroviral regimens and higher risk for low birth weight. This includes a study conducted from 2009 and 2013 in Zambia with 4474 women. They described low birth weight rates of 7%, less than in our study. They found no increased low birth weight in women using ART prior to or during pregnancy when compared to the ones that did not use it [33].

Our study showed no association between preterm birth and PI use despite the much higher preterm birth rates than those seen in the general population without HIV infection. This suggests that the infection itself can be a risk factor for preterm birth in these women. A study from Botswana compared the gestational outcomes in two different periods: 2009–2011 (when zidovudine monotherapy was recommended from the 28th week with CD4 higher or equal to 350 cells/mm3 and combined ART for CD4 lower or equal to 350 cells/mm3) and 2013–2014 after the implementation of TDF/emtricitabine/EFV independently from CD4 count or the gestational week. Preterm birth rate was 22%, with no difference between the combined ART regimens, as in our results [34]. Another clinical trial compared LPV/R and EFV use in 356 infected pregnant women and found no difference in preterm birth rates between the groups [35].

The high complexity of maternal ART regimens was correlated with the increased risk of hematologic and hepatic adverse effects in most of the studies, including our cohort, which showed high rates of anemia and liver changes at birth. Of all the newborns, 25% presented with anemia and 3.6% with low platelet count. Most of the literature showed high rates of anemia in children exposed to antiretroviral maternal treatment. Consistent with our study, the one in Nigeria included 126 uninfected children exposed to maternal HIV and showed decreased in hemoglobin, hematocrits, leucocytes and neutrophils in children exposed to both, maternal HIV and antiretroviral drugs [36]. Although many studies evaluated occurrence of anemia comparing monotherapy with AZT and combined ART, in our study the small number of cases using this regimen (only 23 cases with monotherapy) prevented the comparison. In our multivariate analysis, anemia at birth was associated with exposure of regimens containing AZT (comparing with TDF) and to preterm birth.

Another study analyzing adverse hematologic effects in 221 uninfected children exposed to maternal ART showed 54% of anemia and 40% neutropenia. ART with NNRTI or PI presented as an independent risk factor for anemia and neutropenia during the first three months of life in comparison to monotherapy or double therapy. No significant low platelet count was found but 60% of the children presented with thrombocytosis [37]. Likewise, no significant evidence of low platelets was found in our study.

Like our results, a recent European cohort study on children exposed to maternal ART in their first year of life compared the two periods of exposure (2000–2001 and 2007–2013). It demonstrated lower occurrence of anemia and neutropenia in the second period, with higher frequency of adverse effects when using regimens containing AZT [38].

There are some studies that also showed adverse effects associated with neonatal prophylaxis. An American study followed 147 uninfected children from 1997 to 2009 compared neonatal prophylaxis with monotherapy with AZT and triple therapy (the majority with AZT/3TC/NVP). The adverse effects with combined 3-drugs therapy and monotherapy with AZT were respectively: neutropenia 55% and 39%; anemia 50% and 39%; low platelet count 0 and 3%; elevation in AST 3% and 3%; elevation in ALT 0 and 1%; hyperbilirubinemia 19% and 42%. Anemia occurred more frequently in children who received prophylaxis with combined ART than in the ones who received AZT monotherapy. Despite the adverse effects being typical of AZT toxicity, the combination of AZT/3TC/NVP increased the frequency of severe anemia [39]. Brazilian guidelines do not recommend the combined regimen of three drugs for neonatal prophylaxis. In our cohort, every child received neonatal AZT. Because in our study we had only 24 children using the association between NVP and AZT in the first week of life as neonatal prophylaxis in women with detectable viral load at delivery, this comparison was not performed.

Hepatic changes at birth was a frequent adverse effect in our cohort (36%) associated mostly with NVP exposure. Consistent with our results, one recent American study showed that children exposed to lopinavir/ritonavir presented lower incidence of hematological and hepatic changes [40]. However, in other studies no association was found between hepatic change and specific drug regimens, including a Brazilian study [41]. Studies from Kenya and Spain showed no difference between exposure to NVP and NFV for hepatic toxicity [42, 43].

One limitation in our study was lack of follow-up of children preventing the MTCT diagnosis confirmation. Despite the many efforts to contact the families through phone, children were not brought to the clinic for re-testing. Testing children for HIV viral load at birth to detect intrauterine infection is not recommended in the national guidelines although it could have contributed to diagnosing MTCT. Another limitation was not systematically collecting serum lactate levels in the newborns to evaluate mitochondrial toxicity although, clinically, no signs of this event was observed. Our study used LPV/R more frequently than the others ART regimens making it more difficult to compare their effects. However, the goal of our study was to describe each antiretroviral adverse effect in this population to define the best regimen to reduce MTCT and adverse effects.

Conclusions

In general, we observed that adverse effects in children exposed to HIV maternal antiretroviral treatment were too frequent but not severe and MTCT rates were low independently from the antiretroviral regimen, reinforcing the importance of adequate maternal treatment and total viral load control. The huge benefit of preventing HIV MTCT will always take precedent over low severity of adverse effects such as observed in our study.

Changes in maternal therapy recommended by Brazilian guidelines, using a new class of drugs - integrase inhibitors - as first line regimens for adults and pregnant women, will demand future evaluation on its benefits in preventing HIV MTCT as well as maternal and neonatal adverse effects.

Abbreviations

3TC: 

Lamivudine

AIDS: 

Acquired immunodeficiency syndrome

ALCPH: 

Alkaline phosphatase

ALT: 

Alanine aminotransferase

ART: 

Antiretroviral therapy

AST: 

Aspartate aminotransferase

ATV: 

Atazanavir

AZT: 

Zidovudine

CAISM/UNICAMP: 

Women’s Hospital at University of Campinas School of Medical Sciences

CI: 

Confidence interval

DRV: 

Darunavir

EFV: 

Efavirenz

GGT: 

Gamma-Glutamyl Transferase

HIV: 

Human immunodeficiency virus

LPV: 

Lopinavir

MTCT: 

Mother-to-child transmission

NFV: 

Nelfinavir

NNRTI: 

Non-nucleoside reverse transcriptase inhibitor

NRTI: 

Nucleoside reverse transcriptase inhibitors

NVP: 

Nevirapine

PI: 

Protease inhibitor

R: 

Ritonavir

RAL: 

Raltegravir

RR: 

Relative risk

SGA: 

Small for gestational age

TDF: 

Tenofovir

WHO: 

World Health Organization

Declarations

Acknowledgments

The authors would like to thank Fabia Lopes and Isabeli Miyoshi for the data collecting, Gislaine Carvasan for the statistical analysis, and Maria Sílvia Setubal for the language editing.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

AMD and HM participated in all steps of the study, including research planning, data collection, analysis and writing the manuscripts. FC and MP participated in data collection. EA and GJL performed a review of the article. All authors gave suggestions, read the manuscript carefully, fully agreed on its content and approved its final version.

Ethics approval and consent to participate

This research project was approved by the research committee at the Department of Gynecology and Obstetrics CAISM/UNICAMP and by the University of Campinas School of Medical Sciences ethics review board (Project number 351/2006) and since it is a retrospective study, it was exempt from an informed consent form.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Obstetrics and Gynecology, School of Medical Sciences, University of Campinas, Campinas, Brazil
(2)
Department of Clinics, School of Medical Sciences, University of Campinas, Campinas, Brazil
(3)
Referral Center for STIs and AIDS of Campinas, Campinas, Brazil

References

  1. WHO. Global AIDS update. Ending AIDS towards the 90–90-90 targets. Geneva: UNAIDS; 2017.Google Scholar
  2. The Working Group on Mother-To-Child Transmission of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(5):506–10.View ArticleGoogle Scholar
  3. Tess BH, Rodrigues LC, Newell ML, Dunn DT, Lago TDG. Breastfeeding, genetic, obstetric and other risk factors associated with mother-to-child transmission of HIV-1 in São Paulo state. Brazil AIDS. 1998;12:513–20.View ArticlePubMedGoogle Scholar
  4. Baggaley R, Doherty M, Ball A, Ford N, Gottfried HG. Department of HIV/AIDS, World Health Organization, Geneva, Switzerland. The strategic use of Antiretrovirals to prevent HIV infection: a converging agenda. Clin Infect Dis. 2015;60(Suppl 3):159–60.View ArticleGoogle Scholar
  5. French CE, Thorne C, Byrne L, Cortina-Borja M, Tookey PA. Presentation for care and antenatal management of HIV in the UK, 2009-2014. HIV Med. 2017;18(Suppl 3):161–70.View ArticlePubMedGoogle Scholar
  6. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan M, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173–80.View ArticlePubMedGoogle Scholar
  7. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013.Google Scholar
  8. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. The INSIGHT START study group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.View ArticlePubMedGoogle Scholar
  9. McCormack SA, Best BM. Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals. Clin Pharmacokinet. 2014;53(Suppl 11):989–1004.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Himes SK, Tassiopoulos K, Yogev R, Huestis MA. Pediatric HIV/AIDS Cohort Study (PHACS).Antiretroviral drugs in meconium: detection for different gestational periods of exposure. J Pediatr. 2015;167(Suppl 2):305–11.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Senise JF, Castelo A, Martínez M. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. AIDS Rev. 2011;13(Suppl 4):198–213.PubMedGoogle Scholar
  12. Kourtis AP, Wiener J, Kayira D, Chasela C, Ellington SR, Hyde L, et al. Health outcomes of HIV-exposed uninfected African infants. AIDS. 2013;27(Suppl 5):749–59.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Newell ML, Bunders MJ. Safety of antiretroviral drugs in pregnancy and breastfeeding for mother and child. Curr Opin HIV AIDS. 2013;8(Suppl 5):504–10.View ArticlePubMedGoogle Scholar
  14. Williams PL, Hazra R, Van Dyke RB, Yildirim C, Crain MJ, Seage GR 3rd, Civitello L, Ellis A, Butler L, Rich K, Pediatric HIV/AIDS Cohort Study. Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design. AIDS. 2016;30(Suppl 1):133–44.PubMedPubMed CentralGoogle Scholar
  15. Lubchenco LO, Hansman C, Dressler M, Boyde E. Intrauterine growth as estimate from liveborn birth-weight data at 24 to 42 weeks of gestation. Pediatrics. 1963;32:793–800.PubMedGoogle Scholar
  16. Baeth SV. Hepatic function and physiologyin the newborn. Semin Neonatol. 2003;8:337–46.View ArticleGoogle Scholar
  17. Dos Reis HL, Araujo Kda S, Ribeiro LP, Da Rocha DR, Rosato DP, Passos MR, et al. Preterm birth and fetal growth restriction in HIV-infected Brazilian pregnant women. Rev Inst Med Trop Sao Paulo. 2015;57(Suppl 2):111–20.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Passini R Jr, Cecatti JG, Lajos GJ, Tedesco RP, Nomura ML, Dias TZ, et al. Brazilian multicentre study on preterm birth study group. Brazilian multicentre study on preterm birth (EMIP): prevalence and factors associated with spontaneous preterm birth. PLoS One. 2014;9(Suppl 10):e109069.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Santini-Oliveira M, Friedman RK, Veloso VG, Cunha CB, Pilotto JH, Marins LM, et al. Incidence of antiretroviral adverse drug reactions in pregnant women in two referral centers for HIV prevention of mother-to-child-transmission care and research in Rio de Janeiro, Brazil. Braz J Infect Dis. 2014;18(Suppl 4):372–8.View ArticlePubMedGoogle Scholar
  20. Kourtis AP, Fowler MG. Antiretroviral use during pregnancy and risk of preterm delivery: more questions than answers. J Infect Dis. 2011;204(Suppl 4):493–4.View ArticlePubMedGoogle Scholar
  21. Slyker JA, Patterson J, Ambler G, Richardson BA, Maleche-Obimbo E, Bosire R, et al. Correlates and outcomes of preterm birth, low birth weight, and small for gestational age in HIV-exposed uninfected infants. BMC Pregnancy Childbirth. 2014;14:7.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Xiao PL, Zhou YB, Chen Y, Yang MX, Song XX, Shi Y, et al. Association between maternal HIV infection and low birth weight and prematurity: a meta-analysis of cohort studies. BMC Pregnancy Childbirth. 2015;15:246.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Kennedy CE, Yeh PT, Pandey S, Betran AP, Narasimhan M. Elective caesarean section for women living with HIV: a systematic review of risks and benefits. AIDS. 2017;31:1579–91.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Kreitchmann R, Li SX, Melo VH, Fernandes Coelho D, Watts DH, Joao E, et al. Predictors of adverse pregnancy outcomes in women infected with HIV in Latin America and the Caribbean: a cohort study. BJOG. 2014;121(Suppl 12):1501–8.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Li N, Sando MM, Spiegelman D, Hertzmark E, Liu E, Sando D, et al. Antiretroviral therapy in relation to birth outcomes among HIV-infected women: a cohort study. J Infect Dis. 2016;213(Suppl 7):1057–64.View ArticlePubMedGoogle Scholar
  26. Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206(Suppl 11):1695–705.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Hofer CB, Keiser O, Zwahlen M, Lustosa CS, Frota AC, de Oliveira RH, et al. In utero exposure to antiretroviral drugs: effect on birth weight and growth among HIV-exposed uninfected children in Brazil. Pediatr Infect Dis J. 2016;35(Suppl 1):71–7. https://doi.org/10.1097/INF.0000000000000926.PubMedPubMed CentralGoogle Scholar
  28. Kourtis AP, Schimidt CH, Jamieson DJ, Lau J. Use o f antirretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS. 2007;21:607–15.View ArticlePubMedGoogle Scholar
  29. Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, IMPAACT 1077BF/1077FF PROMISE Study Team. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016;375(Suppl 18):1726–37.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Vannappagari V, Koram N, Albano J, Tilson H, Gee C. Association between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry. BJOG. 2016;123(Suppl 6):910–6.View ArticlePubMedGoogle Scholar
  31. Patel K, Shapiro DE, Brogly SB, Livingston EG, Stek AM, Bardeguez AD, Tuomala RE, P1025 team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group. Prenatal protease inhibitor use and risk of preterm birth among HIV infected women initiating antiretroviraldrugs during pregnancy. J Infect Dis. 2010;201(Suppl 7):1035–44.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Papp E, Mohammadi H, Loutfy MR, Yudin MH, Murphy KE, Walmsley SL, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggestin a potential mechanism contributing to fetal growth restriction. J Infect Dis. 2015;211(Suppl 1):10–8.View ArticlePubMedGoogle Scholar
  33. Bengtson AM, Chibwesha CJ, Westreich D, Mubiana-Mbewe M, Vwalika B, Miller WC, et al. Duration of cART before delivery and low infant birthweight among HIV-infected women in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2016;71(Suppl 5):563–9.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Zash R, Souda S, Chen JY, Binda K, Dryden-Peterson S, Lockman S, et al. Reassuring birth outcomes with Tenofovir/Emtricitabine/Efavirenz used for prevention of mother-to-child transmission of HIV in Botswana. J Acquir Immune Defic Syndr. 2016;71(Suppl 4):428–36.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Koss CA, Natureeba P, Plenty A, Luwedde F, Mwesigwa J, Ades V, et al. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;67(Suppl 2):128–35.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Obumneme-Anyim I, Ibeziako N, Emodi I, Ikefuna A, Oguonu T. Hematological indices at birth of infants of HIV-positive mothers participating in a prevention of mother-to-child transmission program. J Trop Pediatr. 2016;62(Suppl 1):3–9.View ArticlePubMedGoogle Scholar
  37. Feiterna-Sperling C, Weizsaecker K, BüHrer C, Casteleyn S, Loui A, Schmitz T, et al. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1– exposed uninfected newborn infants. J Acquir Immune Defic Syndr. 2007;45:43–51.View ArticlePubMedGoogle Scholar
  38. Rovira N, Noguera-Julian A, Rives S, Berrueco R, Lahoz R, Fortuny C. Influence of new antiretrovirals on hematological toxicity in HIV-exposed uninfected infants. Eur J Pediatr. 2016;175(Suppl 7):1013–7.View ArticlePubMedGoogle Scholar
  39. Smith C, Forster JE, Levin MJ, Davies J, Pappas J, Kinzie K, et al. Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review. PLoS One. 2015;10(Suppl 5):e0127062.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Smith C, Weinberg A, Forster JE, Levin MJ, Davies J, Pappas J, et al. Maternal Lopinavir/ritonavir is associated with fewer adverse events in infant than nelfinavir or Atazanavir. Infect Dis Obstet Gynecol. 2016;2016:9848041. https://doi.org/10.1155/2016/9848041.View ArticlePubMedPubMed CentralGoogle Scholar
  41. El Beitune P, Duarte G, Campbell O, Quintana SM, Rodrigues LC. Effects of antiretroviral agents during pregnancy on liver enzymes and amylase in HIV-exposed, uninfected newborn infants. Braz J Infect Dis. 2007;11(Suppl 3):314–7.View ArticlePubMedGoogle Scholar
  42. Minniear TD, Zeh C, Polle N, Masaba R, Peters PJ, Oyaro B, et al. Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission. Pediatr Infect Dis J. 2012;31(Suppl 11):1155–7.View ArticlePubMedGoogle Scholar
  43. Iveli P, Noguera-Julian A, Soler-Palacín P, Martín-Nalda A, Rovira-Girabal N, Fortuny-Guasch C, et al. Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy. Enferm Infecc Microbiol Clin. 2016;34(Suppl 1):39–44. Spanish.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement